President and Director Emeritus
Dr. Gary Gilliland is a physician-scientist who has made major contributions to understanding the genetic basis of blood diseases, particularly leukemia, and translated seminal findings into new, precision treatments that stop cancer while causing minimal side effects. Dr. Gilliland led Fred Hutch from 2015 to early 2020. Among his achievements were strong growth and diversification of the faculty, an increase in the Hutch’s already-strong federal grant funding, a quadrupled endowment, and new internal and external research collaborations. Through his leadership and vision, Gilliland reinforced the Hutch’s longstanding commitment to scientific excellence. Among Gilliland’s major initiatives was the creation of the Hutch’s Integrated Research Centers, or IRCs, which promote collaboration among researchers across campus and throughout the Fred Hutch/University of Washington Cancer Consortium on high-impact, innovative projects. Before he was named the Hutch’s fifth president, Dr. Gilliland spent 20 years at Harvard Medical School, led a breakthrough immunotherapy drug to market as senior vice president and global oncology franchise head at Merck and Co., and spearheaded a new model for personalized medicine within the University of Pennsylvania system.
National Academy of Medicine
National Academy of Arts and Sciences
American Society for Clinical Investigation
Association of American Physicians
Scientific Review Board
Howard Hughes Medical Institute
1984 M.D. University of California, San Francisco
1980 Ph.D. University of California, Los Angeles (Microbiology), Dr. R. John Collier, Adviser
1975 B.S. University of California, Davis (Bacteriology)
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210